Oncology

Bio-Thera Solutions has begun a Phase 1 trial for BAT8013, a novel ADC targeting CD25 to deplete immunosuppressive cells in the tumor microenvironment.

A new clinical trial combines two targeted therapies, offering potential hope for kidney cancer patients who have exhausted even the newest treatment options.

A new publication on Oncotelic's Sapu003 isn't just science; it's a critical de-risking event validating a manufacturing and drug delivery platform.

Flatiron Health's landmark partnership with Scotland's NHS signals a new era where localized, real-world data becomes a critical asset in the global race for cancer cures.

SKNV's exclusive deal for a university-developed therapy shortens precancerous skin treatment to just four days, challenging norms in both patient care and pharmaceutical commercialization.

As TuHURA Biosciences takes the stage at a key investor conference, its multi-pronged attack on immunotherapy resistance faces a critical test.

With UK approval for its FLAMINGO-01 trial, Greenwich LifeSciences partners with a top cancer center, signaling a key move in the race to prevent breast cancer recurrence.

Biotech firm ReBio Pharma appoints world-renowned expert Prof. Mandeep Sagoo as CMO, accelerating its novel RBP-01 therapy for uveal melanoma into the clinic.

Peer-reviewed data confirms Telix's theranostic approach for advanced prostate cancer, de-risking its Phase 3 trial and setting the stage for a new competitor.

New preclinical data shows atebimetinib outmaneuvers older drugs by hitting cancer hard, then resting. Is this the key to durable tumor control and resilience?

City of Hope's new trial, funded by ARPA-H, uses DNA mapping to predict immunotherapy success, promising a new era of personalized care for lung cancer.

SOTIO Biotech's European patent win for its immunocytokine SOT201 wasn't just a legal victory; it's a signpost in the fierce race to redefine cancer care.

Precision IO Group is showcasing its AI-guided Epione robot and a vision for remote cancer surgery, aiming to erase geographic barriers to expert care.

With FDA Fast Track and a key ESMO presentation, Nouscom is de-risking its pioneering cancer interception therapy, NOUS-209, for Lynch Syndrome.

With promising new data, Nuvation Bio is launching a bold, multi-front clinical strategy for its brain cancer drug. Is this the move that will outmaneuver competitors?

A novel AI-designed drug that can cross the formidable blood-brain barrier has entered U.S. trials, targeting some of the deadliest brain tumors.

SpotitEarly's novel platform combines trained dogs and machine learning for non-invasive cancer detection. A new partnership aims to bring it to market by 2027.

With its lead gene therapy nearing pivotal data, enGene installs a new chairman with a track record of commercial success, signaling a critical shift from R&D to market readiness.

Colorado's largest cancer practice adopts Canopy's enterprise AI, a strategic move to boost efficiency, personalize care, and set a new tech standard.

A new partnership between Nouveau Biosciences and Anova aims to fast-track a novel nanomedicine, offering a beacon of hope for patients with aggressive lymphomas.